Skip to main content
argenx SE logo

argenx SE — Investor Relations & Filings

Ticker · 1AE ISIN · NL0010832176 LEI · 7245009C5FZE6G9ODQ71 BR Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2024-11-26 Report Publication Anno…
Country NL Netherlands
Listing BR 1AE

About argenx SE

https://www.argenx.com/?allow=1

argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.

Recent filings

Filing Released Lang Actions
argenx to Present at Upcoming Investor Conferences
Report Publication Announcement Classification · 99% confidence The document is a press release dated November 26, 2024, announcing that members of argenx's management team will participate in several upcoming investor conferences in December (Citi's 2024 Global Healthcare Conference, Evercore I&I HealthCONx Conference, and Piper Sandler's 35th Annual Healthcare Conference). This type of announcement, which details management's schedule for investor engagement (presentations, fireside chats), is typically classified as an Investor Presentation (IP) or sometimes a Regulatory Filing (RNS) if it's a broad disclosure. However, since it specifically details management's participation in investor events, it aligns best with the intent of an Investor Presentation (IP) or a general announcement about investor relations activities. Given the options, and that it is not a full report, transcript, or specific financial filing, it is an announcement related to investor engagement. Since there isn't a specific code for 'Investor Conference Schedule Announcement', we must choose the closest fit. It is not a presentation itself (IP), but an announcement about future presentations. It is also not a formal regulatory filing like 10-K or ER. Because it is an announcement about management's schedule for investors, it is most closely related to Investor Presentation (IP) materials or a general Regulatory Filing (RNS). Given the content is purely about future investor meetings, and not a formal report release, RNS is the safest fallback, but IP often covers materials related to investor events. Since this is an announcement *about* events where presentations will occur, and not the presentation itself, RNS (General Regulatory Filings) is the most appropriate general classification for this type of corporate communication that doesn't fit the specific report types.
2024-11-26 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC to provide current information. It references a press release issued by the company on November 20, 2024, attached as Exhibit 99.1. The document is only 2145 characters long and primarily serves to announce the press release rather than containing substantive financial data or detailed report content. According to the rules, short documents that announce or attach other reports or press releases should be classified as Regulatory Filings (RNS) rather than the report itself. Therefore, this document is best classified as a Regulatory Filing (RNS).
2024-11-20 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-11-14 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-11-12 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, argenx SE, with the SEC. It primarily serves as a current report to announce the issuance of a press release dated November 11, 2024, which is attached as Exhibit 99.1. The document itself does not contain substantive financial data or detailed report content but rather references the press release. The length is 2337 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes current reports like Form 6-K that announce information without detailed financial statements.
2024-11-12 English
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
Regulatory Filings Classification · 100% confidence The document is a press release dated November 11, 2024, announcing the approval of the drug VYVGART Hytrulo by China's National Medical Products Administration (NMPA) for the treatment of CIDP. It details the clinical trial results, the significance of the approval, and includes standard 'About' sections for the involved companies (argenx and Zai Lab) and forward-looking statements. This format is characteristic of an Earnings Release (ER) or a general corporate announcement, but since it is focused on a major regulatory milestone (drug approval) rather than periodic financial results (like quarterly earnings), it fits best under a category related to corporate actions or regulatory news. Given the options, it is not a 10-K, AR, CT, or IR. It is not a formal regulatory filing like a 10-Q or 8-K, but rather a public announcement of a significant event. Since it announces a major development (drug approval) and provides context, it is most closely aligned with an Earnings Release (ER) in terms of structure (press release format announcing key news) or potentially a Regulatory Filing (RNS) if it were a less detailed announcement. However, because it is a detailed announcement of a major business/regulatory event, and not a report itself, it functions similarly to an Earnings Release announcing positive news, or a general corporate update. Given the options, and the fact that it is a press release announcing a major business event (drug approval), it is often categorized similarly to an ER or a general announcement. Since it is not a financial report, but a news announcement, and it doesn't fit perfectly into the other specific categories (like M&A, Capital Change, etc.), the most appropriate general category for a significant, non-financial-period-specific announcement that isn't a report itself is often RNS, but ER is used for major announcements. Since this is a major business development announcement, and not a financial results summary, RNS (Regulatory Filings/General Announcement) is the safest fallback for a non-standard announcement, but given the structure, it strongly resembles an ER structure announcing positive news. Let's re-evaluate: It is not an Earnings Release (ER) as it doesn't discuss revenue/profit/EPS. It is not a Report Publication Announcement (RPA) as it is the news itself, not an announcement *of* a report. It is a press release detailing a regulatory approval. This type of announcement often falls under RNS (Regulatory Filings/General Announcement) as a catch-all for significant, non-standard corporate news, or potentially LTR if it were about a lawsuit, but this is an approval. I will classify it as RNS as it is a significant regulatory/corporate update that doesn't fit the other specific codes.
2024-11-11 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.